Cannabis Law and Access in Romania

Romania's cannabis law in plain language

Forty-seven countries have now moved some form of cannabis access law through their legislatures. Romania is not one of the bolder names on that list , and yet its regulatory position is more layered than a simple "prohibition" stamp suggests. I've been mapping European scheduling frameworks for the past several months, and Romania keeps coming up as an example of how a country can technically permit medicinal access whilst maintaining some of the stricter personal-use penalties on the continent.

Worth stating clearly before anything else: this article describes Romanian law only. It has no bearing on Australian law, Australian access pathways, or the Therapeutic Goods Administration's framework here at home. If you're an Australian reader interested in how cannabis is regulated domestically, the TGA's Special Access Scheme and Authorised Prescriber pathway are the relevant starting points, and they're very different to what I'm describing below.

The legal baseline: controlled and largely prohibited

Romania classifies cannabis under its national narcotics control legislation , Law No. 143/2000 on combating illicit drug trafficking and consumption, as amended. Cannabis (including tetrahydrocannabinol-containing plant material) sits in Table I of Romania's High Risk Drugs schedule, broadly equivalent in restrictiveness to a Schedule 9 Prohibited Substance classification in Australia's Poisons Standard, though the two systems are not directly comparable.

Possession for personal use is technically a criminal offence. Romanian courts can divert first-time personal-use cases into an integrated assessment and, potentially, an assistance programme rather than straight incarceration , but this is discretionary, and Romania's enforcement record has historically been strict by EU standards. Trafficking offences carry substantial custodial sentences. There is no legal recreational market and no indication from parliament that one is imminent.

Industrial hemp is a different story. Romania has actually been one of Europe's more significant hemp producers for decades; flax and hemp cultivation in the Danube plains predates modern prohibition by centuries. Under EU Regulation 2021/2115 (the Common Agricultural Policy framework) and Romania's domestic implementing rules, hemp cultivation is permitted where varieties are certified by the EU's common catalogue and the THC content of the plant does not exceed 0.3% on a dry-weight basis. That threshold aligns with the broader EU position adopted progressively since 2021. Fibre and seed production dominate; this is not a pathway to cannabidiol consumer products, despite how it sometimes gets framed online.

Medicinal cannabis: a narrow but real pathway

Romania transposed EU Directive 2001/83/EC on medicinal products and maintains a medicines licensing regime through the National Agency for Medicines and Medical Devices of Romania (ANMDMR). A cannabis-based medicinal product can, in principle, receive marketing authorisation through this agency, but as of the time of writing, no domestically approved cannabis-derived medicinal product held a full ANMDMR marketing authorisation in the way that, say, nabiximols holds a product licence in some other EU member states.

There is a controlled import and hospital dispensing pathway for specific named medicinal products. Prescribing is tightly restricted to specialist physicians, and supply runs through hospital pharmacies rather than community dispensing. In practice, patient access is narrow and documented cases of successful access through the formal system are limited.

The CBD molecule itself, and the regulatory status of CBD-only products with negligible THC; sits in a genuinely unsettled legal space in Romania, as it does across much of the EU following the Court of Justice of the European Union's 2020 ruling in Kanavape (Case C-663/18). That ruling found that CBD derived from the whole cannabis plant could not automatically be classified as a narcotic under the 1961 Single Convention. Romania has not fully clarified its domestic position on low-THC CBD products in response, and enforcement has been inconsistent.

I'll be honest: the CBD product market in Romania operates in a grey zone that I'd describe as tolerated rather than lawful. That's not a ringing endorsement for anyone considering either selling into or purchasing from that market.

How Romania fits into the EU framework

EU member states retain sovereign control over drug scheduling and criminal law. The EU does, however, exert influence through: pharmaceutical product law (which governs medicinal cannabis products marketed across borders), novel food regulation (which affects hemp-derived CBD extracts sold as food supplements), and agricultural policy (which governs hemp cultivation). Romania navigates all three of these in a somewhat piecemeal way.

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), now operating as the EU Drugs Agency (EUDA), publishes annual country drug reports. Romania's reports consistently note high rates of cannabis seizure at borders, relatively low but rising domestic use prevalence, and a policy environment that remains centred on criminal-law responses rather than harm-reduction or regulated-access models. That's a meaningful contextual point for anyone trying to understand where Romania sits relative to, say, Germany (which moved to a partial legalisation model in 2024) or the Netherlands.

What this means for the plant's chemistry; briefly

Legal frameworks don't change the underlying phytochemistry, obviously. Whether a jurisdiction permits or prohibits cannabis, the plant produces the same range of cannabinoids, from the well-characterised THC and CBD through to minor cannabinoids like cannabigerol and the various acids like THCA, alongside a complex terpene profile that includes compounds like beta-caryophyllene and myrcene. The scheduling of a molecule doesn't alter what it is. But it does determine who can study it, who can access it, and under what conditions it can be prescribed; which is the whole point of this kind of comparative legal mapping.

Romania's industrial hemp sector does make the country a minor source of raw botanical material that ends up in supply chains for cannabidiol extracts processed elsewhere in Europe. Whether a given extract is full-spectrum, broad-spectrum, or isolate depends on the processing applied downstream, not on which EU member state grew the hemp. I mention this only because I've seen it cause genuine confusion in discussions about provenance and product composition.

A note on travelling to Romania as an Australian patient

Australian patients who hold a valid prescription for a cannabis-based medicine under the TGA framework, whether accessed via the Special Access Scheme or through an Authorised Prescriber, cannot simply carry that medicine to Romania and assume legal protection. International travel with cannabis-derived medicines requires prior authorisation from both the departing country and the destination country under the International Narcotics Control Board's guidelines (derived from the 1961 Single Convention). Romania's controlled import rules are strict. If you're planning to travel and you hold one of these prescriptions, get advice from your prescribing physician and contact the Romanian embassy in Canberra well ahead of travel. I'd suggest doing it at least three months out.

I spent a weekend recently poring over vintage Austro-Hungarian survey maps of the Danube basin; the kind of thing I can't stop collecting, and it struck me how much of the region's hemp-growing geography was already mapped in detail by the 1880s. The crop has deep roots there. The modern legal framework, by contrast, is relatively recent and still evolving. Those two facts coexist without contradiction; they're just worth keeping separate.

The short version

Romania maintains strict criminal prohibitions on cannabis possession and use. A narrow medicinal access pathway exists in theory, but practical patient access is limited. Industrial hemp cultivation is permitted under EU agricultural rules at or below 0.3% THC. The CBD consumer product market operates in an unresolved legal grey zone. There is no recreational legalisation framework and none appears imminent.

For Australian readers: this is a foreign jurisdiction. None of it is Australian law. The TGA's scheduling regime, the Poisons Standard, and the pathways relevant to you, the Schedule 8 controlled drug classification of THC-containing products, the Schedule 4 prescription-only status of low-THC CBD medicines; all operate entirely separately from what I've described above.

Sources

• Romania Drug Report 2023, European Union Drugs Agency (EUDA/EMCDDA)
• Case C-663/18 Kanavape Judgment, Court of Justice of the European Union
• Guidance on use of medicinal cannabis in Australia: patient information; Therapeutic Goods Administration
• Guidelines for Governments on Preventing the Illicit Import of Internationally Controlled Substances, International Narcotics Control Board

, Marcus Hale, Regulatory researcher, TGA & access law